ArticleCurrent hepatology reports2025
Transient Elastography and Fibroscan: Stethoscope of a Hepatologist in Today's World.
Article in Current hepatology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Very Low Energy Ketogenic Therapy Effects on Fibrosis-Dependent Metabolic Reprogramming: A Serum NMR Pilot Study.Nutrients · 2026Article
- From Birth to Midlife-Liver Function, Fibrosis and Mortality in Individuals with Severe Alpha-1-Antitrypsin Deficiency Identified by Neonatal Screening.Journal of clinical medicine · 2026Article
- Imaging-based fibrosis assessment and risk stratification in MASLD.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Purpose of Review: Vibration-controlled transient elastography (VCTE) has become a cornerstone in the noninvasive assessment of liver disease across etiologies. This review highlights its role in risk stratification and longitudinal monitoring, emphasizing its value in both clinical practice and research settings, including community and academic hepatology. Recent Findings: VCTE reliably assesses liver fibrosis severity and clinically significant portal hypertension and enables ongoing monitoring of therapeutic response. It also predicts liver-related events and mortality. Recognizing its limitations and potential confounders is essential to ensure diagnostic accuracy, and its performance can be further enhanced by integrating clinical and biochemical variables. Summary: Despite inherent limitations, improvements in probe design, standardized protocols, and composite algorithms have expanded its clinical utility. The 2022 Baveno consensus established clear guidance for using VCTE to identify clinically significant portal hypertension, ultimately aiming to prevent first decompensation and improve patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.